Whalesbook
The Competition Commission of India's (CCI) approval marks a significant milestone for Curefit Healthcare, bringing both capital and the endorsement of a major global investor. Temasek Holdings, a sovereign wealth fund known for its long-term investments, is backing Curefit's integrated fitness and wellness model in India's fast-changing consumer health market. This clearance comes as Curefit, which operates the Cult.fit brand, prepares for a potential public listing and works towards profitability.
Capital Infusion and Financials
The CCI's approval allows MacRitchie Investments, an indirect wholly owned subsidiary of Temasek, to acquire a stake in Curefit Healthcare to provide capital for its operations in the fitness sector. Despite reporting a 31% year-on-year increase in operating revenue to ₹1,216 crore in FY25, Curefit incurred a net loss of ₹480 crore. However, the company has made progress in operational efficiency, narrowing its EBITDA loss to ₹36 crore in FY25 from ₹209 crore in FY24. Its EBITDA margin improved to -3%.
Curefit operates over 700 centers across 40 cities, with about 90% of its revenue generated from six key metro areas. The company's valuation has remained steady at $1.6 billion for about four years, with a recent $2 million funding round in July 2025 occurring at this valuation. This suggests a focus on operational growth rather than aggressive valuation increases.
Market Position and Growth Prospects
Curefit, through its Cult.fit brand, is a significant player in India's health-tech market. It achieved unicorn status in November 2021 with a valuation of $1.64 billion and was last reported with a valuation of ₹12,200 crore (approximately $1.43 billion) as of March 2025. Its direct competitor, HealthifyMe, has raised $145 million over 11 rounds, though its recent valuation is not publicly disclosed.
The broader Indian fitness tracker market is projected to grow at a CAGR of 19.8% to reach $7.6 billion by 2030, and the fitness equipment market is expected to surpass $1 billion by 2030, driven by rising health consciousness and digital integration. Temasek's significant focus on India, committing $10 billion by 2026-27 and having already deployed $6 billion, positions Curefit well to leverage these market trends. Temasek's investment strategy in India emphasizes digitization, healthcare, and sustainable living, which aligns with Curefit's comprehensive wellness approach.
Challenges and Concerns
Despite strong revenue growth, Curefit continues to operate at a net loss, which could affect investor interest ahead of its planned IPO. The company's revenue relies heavily on six major metropolitan areas, potentially exposing it to localized economic downturns and limiting its reach into Tier 2 and Tier 3 cities, which offer significant growth potential. The $1.6 billion valuation, while substantial, has remained unchanged for about four years. This raises questions about value creation for existing investors compared to sector peers. While Temasek is a strategic investor focused on long-term financial returns, its mandate does not necessarily include driving operational expansion beyond commercially viable limits.
Future Outlook
Curefit is reportedly targeting a public listing by 2026, with expectations of reaching a $2 billion valuation. The company aims to achieve EBITDA profitability by the end of FY26. The CCI approval of Temasek's investment provides Curefit with a strong capital foundation to support its expansion, digital efforts, and progress toward profitability and a potential IPO. As a large sovereign wealth fund, Temasek's involvement often boosts market confidence and can attract additional investment into India's expanding digital health and wellness sector.